Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias.
Sign Up to like & getrecommendations! Published in 2019 at "Current pharmaceutical design"
DOI: 10.2174/1381612825666190130101108
Abstract: Coronary heart disease (CHD) remains the leading cause of disability and death in industrialized Countries. Among many conditions, which contribute to the etiology and progression of CHD, the presence of high low density lipoprotein-cholesterol (LDL-C)… read more here.
Keywords: nutraceuticals treatment; drugs nutraceuticals; patients dyslipidemias; dyslipidemias current ... See more keywords
Bone Health in Patients with Dyslipidemias: An Underestimated Aspect
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23031639
Abstract: Beyond being aging-related diseases, atherosclerosis and osteoporosis share common pathogenetic pathways implicated in bone and vascular mineralization. However, the contributory role of dyslipidemia in this interplay is less documented. The purpose of this narrative review… read more here.
Keywords: bone; bone health; fracture risk; patients dyslipidemias ... See more keywords